End Results Program News Today

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Investegate announcements from Truqap recommended for EU breast cancer approval

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or ...

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations Approval based on CAPItello-291 results which showed...

Application based on results from global Phase 3 RATIONALE-305 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer Prescription...

(2024-02-13 | TSXV:TELO) Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Urinary incontinence persisted through 10 years after radical prostatectomy, however. An observational study examined prostate cancer functional outcomes, such as sexual function after radical prostatectomy, at 10 years.

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.